ZNTL (Zentalis Pharmaceuticals) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Zentalis Pharmaceuticals 3-Year Dividend Growth Rate?

Zentalis Pharmaceuticals's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The historical rank and industry rank for Zentalis Pharmaceuticals's 3-Year Dividend Growth Rate or its related term are showing as below:

ZNTL's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 13.2
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Zentalis Pharmaceuticals's Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00. As of today, Zentalis Pharmaceuticals's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Zentalis Pharmaceuticals's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Zentalis Pharmaceuticals's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zentalis Pharmaceuticals's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zentalis Pharmaceuticals's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Zentalis Pharmaceuticals's 3-Year Dividend Growth Rate falls into.

Zentalis Pharmaceuticals 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Zentalis Pharmaceuticals (NAS:ZNTL) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Zentalis Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2024 )	/	EPS without NRI (Q: Sep. 2024 )
	=	0	/	-0.718
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zentalis Pharmaceuticals 3-Year Dividend Growth Rate Related Terms>

Zentalis Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zentalis Pharmaceuticals Inc (NAS:ZNTL) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

1359 Broadway, Suite 801, New York, NY, USA, 10018

Website

https://www.zentalis.com

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

Executives

Cam Gallagher	director	6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Diana Hausman	director	C/O ONCOTHYREON INC., 2601 FOURTH AVE, SUITE 500, SEATTLE WA 98121
Melissa B, Epperly	officer: Chief Financial Officer	C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Andrea Paul	officer: General Counsel	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Kimberly Blackwell	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
David Michael Johnson	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Carrie Brownstein	officer: Chief Medical Officer	500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701
Kevin D. Bunker	officer: Chief Operating Officer	C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Jan Skvarka	director	C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Iris Roth	officer: Chief Operating Officer	C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Anthony Y Sun	director, officer: President & CEO	C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10106
Alexis Pinto	officer: Chief Legal Officer	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Dimitris Voliotis	officer: SVP, Clinical Development	C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Enoch Kariuki	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901